Enzalutamide prolonged survival in advanced prostate cancer

At the 2014 Genitourinary Cancers Symposium, publicly shared findings showed that Enzalutamide (Xtandi®) prolongs survival before chemotherapy in men with advanced (metastatic), hormone-resistant prostate cancer.
What is the prostate?
The prostate is part of the male reproductive system, a gland just below the bladder and in front of the bowel, surrounding the bladder outlet. It mainly produces protective fluid for sperm, diluting and storing them healthily, and with sphincter muscles closes the bladder outlet to prevent leakage.
The prostate gland
It enlarges with age, called benign prostatic hyperplasia, usually in the transition zone surrounding the urethra. Enlargement can block the bladder or urinary tract and prevent flow. Men may experience frequent, painful or bloody urine or semen, and lower-back stiffness and pain. These symptoms may reflect benign enlargement or cancer.
What is prostate cancer, and how does it form?
Uncontrolled prostate cell growth first spreads within the gland, then through its capsule and beyond. It is hormone-sensitive and can be controlled for long periods with androgen deprivation therapy (ADT). When response stops, it is called hormone-resistant. Advanced hormone-resistant cancer is difficult to treat because it has spread distantly and no longer responds to hormonal treatment.
- Related topic: Prostate Cancer Symptoms, Stages and Treatment
Enzalutamide in prostate cancer
Enzalutamide (Xtandi®) interferes with cancer-promoting molecular pathways, targeting multiple steps in androgen receptor signaling. It does not cause common chemotherapy effects such as nausea and hair loss.
According to findings shared at the 2014 Genitourinary Cancers Symposium, enzalutamide (Xtandi®) reduces radiographic progression (progression on imaging) and prolongs survival in chemotherapy-naive men with advanced hormone-resistant disease. Between September 2010 and September 2012, the study enrolled chemotherapy-naive, asymptomatic or mildly symptomatic patients with advanced (metastatic), hormone-resistant prostate cancer, numbering 1,715. Some received enzalutamide; others placebo (inactive substance presented as medicine) and standard hormonal treatment. Main endpoints were overall and radiographic progression-free survival.
The drug reduced mortality risk by %30 and radiographic progression by %81. Overall response was %59 (%20 complete and %39 partial), versus %5 with placebo. Estimated average overall survival was 32.4 versus 30.2 months. Chemotherapy need was delayed an average 17 months: treatment began after an average 28 months versus 10.8 with placebo.
Researchers concluded that enzalutamide substantially prolonged overall and radiographic progression-free survival in chemotherapy-naive men with advanced hormone-resistant prostate cancer. Following these positive results, the study ended and placebo recipients began enzalutamide.
Dear readers, prostate cancer is more common in older men. Age-related health and advanced disease make aggressive forms more challenging to treat. These positive findings are therefore welcome advances expanding effective options. Every new development excites science and lets patients look forward with greater hope.
Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.